I-FABP is decreased in COVID-19 patients, independently of the prognosis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
12
2020
accepted:
25
03
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Severe acute respiratory syndrome caused by the novel coronavirus (SARS-CoV-2) is frequently associated with gastrointestinal manifestations. Herein we evaluated the interest in measuring the intestinal fatty acid-binding protein (I-FABP), a biomarker of intestinal injury, in COVID-19 patients. Serum I-FABP was analyzed in 28 consecutive patients hospitalized for a PCR-confirmed COVID-19, in 24 hospitalized patients with non-COVID-19 pulmonary diseases, and 79 patients admitted to the emergency room for abdominal pain. I-FABP serum concentrations were significantly lower in patients with COVID-19, as compared to patients with non-COVID-19 pulmonary diseases [70.3 pg/mL (47-167.9) vs. 161.1 pg/mL (88.98-305.2), respectively, p = 0.008]. I-FABP concentrations in these two populations were significantly lower than in patients with abdominal pain without COVID-19 [344.8 pg/mL (268.9-579.6)]. I-FABP was neither associated with severity nor the duration of symptoms. I-FABP was correlated with polymorphonuclear cell counts. In this pilot study, we observed a low I-FABP concentration in COVID-19 patients either with or without gastrointestinal symptoms, of which the pathophysiological mechanisms and clinical impact remain to be established. Further explorations on a larger cohort of patients will be needed to unravel the molecular mechanism of such observation, including the effects of malabsorption and/or abnormal lipid metabolism.
Sections du résumé
BACKGROUND
Severe acute respiratory syndrome caused by the novel coronavirus (SARS-CoV-2) is frequently associated with gastrointestinal manifestations. Herein we evaluated the interest in measuring the intestinal fatty acid-binding protein (I-FABP), a biomarker of intestinal injury, in COVID-19 patients.
METHODS
Serum I-FABP was analyzed in 28 consecutive patients hospitalized for a PCR-confirmed COVID-19, in 24 hospitalized patients with non-COVID-19 pulmonary diseases, and 79 patients admitted to the emergency room for abdominal pain.
RESULTS
I-FABP serum concentrations were significantly lower in patients with COVID-19, as compared to patients with non-COVID-19 pulmonary diseases [70.3 pg/mL (47-167.9) vs. 161.1 pg/mL (88.98-305.2), respectively, p = 0.008]. I-FABP concentrations in these two populations were significantly lower than in patients with abdominal pain without COVID-19 [344.8 pg/mL (268.9-579.6)]. I-FABP was neither associated with severity nor the duration of symptoms. I-FABP was correlated with polymorphonuclear cell counts.
CONCLUSIONS
In this pilot study, we observed a low I-FABP concentration in COVID-19 patients either with or without gastrointestinal symptoms, of which the pathophysiological mechanisms and clinical impact remain to be established. Further explorations on a larger cohort of patients will be needed to unravel the molecular mechanism of such observation, including the effects of malabsorption and/or abnormal lipid metabolism.
Identifiants
pubmed: 33857216
doi: 10.1371/journal.pone.0249799
pii: PONE-D-20-39264
pmc: PMC8049236
doi:
Substances chimiques
Biomarkers
0
FABP2 protein, human
0
Fatty Acid-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249799Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Lipidol. 2020 May - Jun;14(3):297-304
pubmed: 32430154
J Crit Care. 2017 Dec;42:92-100
pubmed: 28710988
Aliment Pharmacol Ther. 2013 Feb;37(4):482-90
pubmed: 23289539
Dig Liver Dis. 2020 Oct;52(10):1104-1105
pubmed: 32646736
J Infect Dis. 2020 Jan 1;221(1):110-121
pubmed: 31504638
Medicine (Baltimore). 2018 Aug;97(33):e11782
pubmed: 30113465
J Intern Med. 2021 Apr;289(4):523-531
pubmed: 32976665
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
Open Forum Infect Dis. 2019 Dec 03;7(1):ofz507
pubmed: 31950071
Int Immunol. 2021 Mar 31;33(4):241-247
pubmed: 33538817
Clin Chem Lab Med. 2018 Feb 23;56(3):373-385
pubmed: 28841570
PLoS One. 2020 Sep 24;15(9):e0239573
pubmed: 32970772
Circulation. 2020 Dec;142(22):2128-2137
pubmed: 33058695
Surg Infect (Larchmt). 2015 Jun;16(3):247-53
pubmed: 25831240
Lancet Rheumatol. 2020 Dec;2(12):e754-e763
pubmed: 33015645
Dig Liver Dis. 2020 Oct;52(10):1076-1079
pubmed: 32507692
J Clin Invest. 1974 Aug;54(2):326-38
pubmed: 4211161
JAMA. 2020 Sep 24;:
pubmed: 32970139
Am J Physiol Gastrointest Liver Physiol. 2020 Mar 1;318(3):G518-G530
pubmed: 31905021
Am J Gastroenterol. 2020 Jul;115(7):1003-1006
pubmed: 32618648
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437